New York Times  Sep 1  Comment 
The auction of the lender is meant to complete a rescue of Banco Espírito Santo, which required a state-led bailout in August 2014 of about $5.5 billion.
GenEng News  Aug 31  Comment 
Denmark-based FeF Chemicals was first established in 1949, acquired by Novo Industries in 1986, and has been part of the Novo Nordisk pharmaceutical group since its creation in 1989. This month FeF Chemicals is changing its name to Novo Nordisk...
FierceBiotech  Aug 28  Comment 
Now that Intarcia has come out ahead of Merck's Januvia in the latest study of its implanted extended-release option ITCA-650, some analysts are wondering how the next wrinkle in the big diabetes drug competition will play out.
FierceBiotech  Aug 28  Comment 
Novo Nordisk has gone on a shopping spree in Indiana, picking up a pair of biotechs co-founded by Eli Lilly R&D veteran Richard DiMarchi. The startups, the oldest of which was founded in 2013, are both developing protein-based diabetes drugs based...
FiercePharma  Aug 27  Comment 
After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes...
GenEng News  Aug 27  Comment 
Novo Nordisk said today it plans to acquire two privately held biopharmaceutical research companies, Calibrium and MB2, for an undisclosed price—a deal that further focuses Novo Nordisk on developing diabetes and obesity drugs. Calibrium was...
Reuters  Aug 27  Comment 
Novo Nordisk said on Thursday it has agreed to buy two private biopharmaceutical research companies specializing in diabetes Calibrium LLC and MB2 LLC.
FierceBiotech  Aug 27  Comment 
Novo Nordisk has hit a roadblock in its drive to expand the label for Victoza to cover use in Type 1 diabetics. The snag arose when Victoza failed to deliver hypoglycaemic benefit experienced by Type 2 diabetics in people with the other form of...
FiercePharma  Aug 26  Comment 
With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $1.2 billion on its first API plant in the U.S., a project that is expected to bring 700 jobs. As part of the 5-year project, it will...
MedPage Today  Aug 25  Comment 
(MedPage Today) -- Lackluster results for liraglutide as adjunct to insulin therapy

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki